Objectives: Sepsis is a lethal syndrome annually affecting approximately 900,000 patients in the United States alone. Despite their benefit in rheumatoid disease, selective antitumor necrosis factor agents failed to improve outcome in early sepsis trials in the 1990s. However, data from additional sepsis trials testing these agents are now available. We therefore sought to determine the effect on survival of selective antitumor necrosis factor agents in randomized clinical sepsis trials.. Data Sources: PubMed, Scopus, Embase, and Web of Science. Study Selection: Randomized human sepsis trials of selective antitumor necrosis factor agents reporting survival rates.
S elective inhibitors of tumor necrosis factor (TNF)-α to limit inflammation and joint injury have become a mainstay for managing rheumatoid arthritis (1) . Early in their development, similar anti-TNF agents were also tested in patients with severe infection causing sepsis and septic shock (2) (3) (4) (5) (6) (7) (8) (9) (10) . Preclinical sepsis studies had shown that TNF levels were elevated and selective inhibition of TNF prevented injury and death (11) . This and other data led to the hypothesis that excessive TNF release during infection caused an injurious host inflammatory response central to the pathogenesis of sepsis (11, 12) . Application of selective anti-TNF agents for sepsis was viewed as a therapeutic breakthrough for a syndrome which may affect up to 900,000 patients annually in the United States alone with a mortality rate of 15% to 45%, depending on disease severity (13, 14) . Despite high expectations, however, anti-TNF agents failed during the 1990s to improve survival in clinical sepsis trials.
This early clinical experience with anti-TNF agents in sepsis was a setback to the biotechnology and pharmaceutical industries, which had made substantial investments in the research effort. More fundamentally, the experience raised questions regarding the role of TNF in the pathogenesis of sepsis (15) . However, interest in the potential for anti-TNF therapy for sepsis, although dampened, has continued. Since the results from trials with anti-TNF agents in sepsis were last systematically examined almost a decade ago (16, 17) , survival data from additional randomized trials testing similar agents and including an additional 2,758 patients have been published (18) (19) (20) . Based on the continued interest in such therapies and with the increased power provided by more recent trials and patients, we have performed a meta-analysis examining whether selective anti-TNF agents improve survival in patients with sepsis.
METHODS

Data Sources and Searches
PubMed, Scopus, Embase, and Web of Knowledge (Web of Science, Biological Abstracts, and MEDLINE) databases were searched using the terms "tumor necrosis factor inhibitor," "sepsis," and "human clinical trial" to identify clinical trials of anti-TNF therapies in sepsis (last searched August 2011). To maximize our ability to find studies, the specific MeSH and Emtree controlled vocabulary terms were adapted (J.W.) to the unique searching features of each database (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/ CCM/A693). Searches were not limited by date, language, or publication status.
Study Selection
Studies meeting the following criteria were included: randomized trial design, enrollment of adult patients (> 18 yr old) with sepsis or septic shock, similar treatment for all study groups with the exception of a predetermined anti-TNF regimen, and comparison of survival rates between patients randomized to receive an anti-TNF agent or either placebo or a very low dose of anti-TNF agent. Criteria for sepsis or septic shock needed to be consistent with the American College of Chest Physicians and Society of Critical Care Medicine Consensus Conference sepsis definition (21) .
Data Extraction and Quality Assessment
Two investigators knowledgeable of critical care medicine (P.Q., P.Q.E.) independently reviewed the included studies using a standardized data collection protocol. A third author evaluated and resolved discrepancies (C.N.). Data were collected on study characteristics, treatment interventions, and patient outcomes (Tables 1 and 2; Fig. 1 ). The Jadad score was used to compare the quality of included trials (Supplemental Table 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/ A693) (22) . Financial relationships between manufacturers and authors were recorded to examine sources of potential bias.
Data Synthesis and Analysis
In trials testing more than one dose of an anti-TNF agent, we assessed the effect of dose (treated as continuous) on survival rate across those studies testing the same type of agent. Random-effect logistic regression models were used to account for the correlation of subgroups within a study using SAS PROC GLIMMIX (SAS version 9.2, Cary, NC). This is the only analysis where we used odds ratio. In all other analyses, the treatment effects were compared using the relative risk (RR) of death. All treatment doses within each study were pooled when appropriate. Random-effect models were used to compare treatment effects. For one study examining four doses of an agent but not a placebo, the lowest treatment dose was used as control in analysis (5) . Sensitivity analysis was conducted with this study excluded. Heterogeneity among studies was assessed using the Q statistic and I 2 value. Studies were only combined when I 2 was less than 30%. In subgroup analysis, the influence of type of anti-TNF agent and study size was examined. The effects of therapy were also examined in trials comparing similar subgroups of patients based on the presence or absence of shock, cytokine levels (TNF and interleukin [IL]-6), type of underlying bacterial infection, and severity of illness. Potential publication bias and its influence on the treatment effect across studies were evaluated with funnel plot and Eggers regression. Numbers needed to treat (NNT) were calculated as the inverse of risk difference, which was itself calculated based on the estimated overall RR and the median control group mortality rate of the studies included in this meta-analysis. This calculation also generated the treatment and control group mortality rates that were used for the power calculation. All analyses were done using R package meta version 1.6-1 (http://cran. r-project.org/web/packages/meta/index.html) and metafor version 1.6-0 (http://www.metafor-project.org/) (Bell Laboratories, Berkeley Heights, NJ) unless noted otherwise.
RESULTS
Overview of Included Studies
Four hundred fifty-two studies were identified by our literature searches; fifteen met inclusion criteria (2-10, 18-20, 23-25) (Supplemental Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/A693). These studies encompassed 8,896 patients with sepsis and investigated four types of anti-TNF agents. In 12 trials, two types of anti-TNF antibodies were studied: 10 trials (6,818 patients) testing anti-TNF monoclonal antibodies (TNF-mAb) (2-8, 19, 23, 24) and two trials (151 patients) testing anti-TNF polyclonal antibodies (TNF-pAb) (18, 20) . In three trials, two types of soluble TNF receptors were studied: two trials (1,786 patients) testing a low-molecular-weight TNF soluble receptor (TNFsr-p55) (9, 25) and one trial (141 patients) testing a higher molecular weight TNF soluble receptor (TNFsr-p75) ( 
Effect of Anti-TNF Agents on Mortality
For the 15 trials combined, there were 1,493 deaths in 3,983 control patients (37.5%) and 1,727 deaths in 4,913 patients receiving anti-TNF agents (35.2%). The effects on mortality were not significantly different across these trials (I 2 = 0%, p = 0.84), and overall, anti-TNF agents produced a significant decrease in the RR of death (RR [95% CI], 0.93 [0.88-0.98]; p = 0.01) ( Fig. 1) . Notably, in all seven trials enrolling more than 400 patients, anti-TNF agents produced consistent nominal improvements in survival rates, a pattern unlikely to have occurred by chance (p = 0.02, based on a geometric distribution). Based on these trial data, with a median control mortality rate of 38.6%, the number of patients with sepsis needed to treat with anti-TNF therapy to save one life would be 38. 
Subgroup Analysis Comparing Anti-TNF Trials
Trials testing each type of anti-TNF agent were examined separately. Across 10 trials, TNF-mAb had effects on the RR of death that were consistent (I 2 = 0%, p = 0.83) and significantly beneficial (0.93 [0.87-0.99], p = 0.015) ( Fig. 2) in a pattern similar to anti-TNF agents overall ( Fig. 1 ). For the two TNF-mAb agents investigated in more than a single trial (afelimomab, n = 4; BAY×1351, n = 3), the effects of therapy were consistent (I 2 = 9.6%, p = 0.35 and I 2 = 0%, p = 0.97, respectively) and both on the side of benefit (0.91 [0.82-1.01], p = 0.08 and 0.94 [0.86-1.02], p = 0.14, respectively). TNF-pAb and TNFsr-p55 had effects on the RR of death, which also did not differ across the trials testing each agent (I 2 = 0%, p = 0.43 and 0.73, respectively). However, these survival effects although similar to that of anti-TNF agents overall did not reach statistical significance (0.82 [0.49-1.37], p = 0.45 and 0.93 [0.81-1.08], p = 0.33, respectively), possibly because far fewer patients were studied. TNFsr-p75 was studied in only one trial. Its effect on the RR of death was not significantly different from other anti-TNF agents ( Fig. 2) but was on the side of harm (1.50 [0.86-2.61], p = 0.16).
Trials Comparing the Effects of Anti-TNF Agents in Similar Subgroups of Patients With Sepsis
We also examined the results of trials comparing the effects of anti-TNF agents in similar patient subgroups. Four trials compared the effects of anti-TNF agents in septic patients with shock versus without shock at enrollment (2, 3, 9, 25) (Supplemental Fig. 2 , Supplemental Digital Content 1, http://links.lww. com/CCM/A693). The effects of anti-TNF agents on the RR of death were not significantly different across trials in these two subgroup categories (I 2 = 0, p = 0.81 and 0.72).
Overall, anti-TNF agents had no significant effect on the RR of death in septic patients without shock (RR, 0.99 [0.83-1.19]; p = 0.93) but did produce a beneficial trend in those with shock (RR, 0.90 [0.80-1.02]; p = 0.10). However, there was no significant difference comparing the overall survival effects of anti-TNF agents in patients with versus without shock (p = 0.41).
Five and three trials compared the effects anti-TNF agents in patients with high versus low blood IL-6 (4, 6, 25, 18, 9) or TNF levels (4, 5, 9) respectively, and four trials compared these effects in patients with evidence of either Gram-positive or Gram-negative infection at enrollment (3, 4, 9, 25) . Across trials, the effects of treatment on mortality were variable in subgroups with high IL-6 levels (I 2 = 59%, p = 0.05), low TNF levels (I 2 = 47%, p = 0.15), or Gram-negative infections (I 2 = 45%, p = 0.14). Therefore, these trials were not combined and no overall inferences were made.
Finally, at enrollment, Acute Physiology and Chronic Health Evaluation (APACHE) 2 scores were reported in one trial (3) and Simplified Acute Physiology Scores (SAPS) were reported in another trial (25) . Anti-TNF agents did not affect the RR of death significantly in patients with either high or low APACHE 2 scores (1.08 [0.81-1.44], p = 0.60 and 0.83 [0.56-1.24], Table 2 ). In eight trials, the RR with different anti-TNF therapy doses was similar (p = nonsignificant), so we averaged over dose to increase our ability to find significant effects (2, 3, 5-7, 10, 18, 23) . In one trial (Abraham et al [9] ), enrollment was stopped early for the lowest dose of anti-TNF agents studied (low-molecular-weight TNF soluble receptor, TNFsr-p55). This low dose had a survival effect on the side of harm, whereas the two higher doses studied had effects on the side of benefit (p = 0.02 for the difference) (9) . Because this low-dose subgroup was not included in our primary analysis in the original trial report, it was not included in the analysis presented in this figure (however, see our sensitivity analysis results where we show the results if it is included). As shown, overall anti-TNF agents had highly consistent effects and were associated with a significant decrease in the RR of death. In all seven trials enrolling more than 400 patients, anti-TNF agents had effects on the side of benefit. Sensitivity analysis: including the low-dose TNFsr-p55 subgroup from the trial noted above (Abraham et al [9] ) in the meta-analysis did not change the overall results (p = nonsignificant). The effects of anti-TNF agents were still consistent across the 15 trials (I 2 = 0%) and the RR still significant (0.94 [0.89-0.99], p = 0.02). Also, removing the trial in which the lowest dose of treatment was used as control (Fisher et al [5] ), it did not change the overall results (p = nonsignificant); the findings were still consistent for the 14 remaining trials (I 2 = 0%) and the RR was still significant (0.93 [0.88-0.98], p = 0.01). mAb = monoclonal antibody, p55 = low-molecular weight TNF soluble, p75 = high-molecular-weight TNF soluble receptor, pAb = polyclonal antibody. p = 0.36, respectively). However, treatment did increase the RR of death significantly in those with high (0.79 [0.65-0.96], p = 0.02) but not low SAPS (1.25 [0.91-1.73], p = 0.17).
Other Outcome Measures Examined
Eight trials provided data regarding the effect of anti-TNF agents on resolution of shock (six trials) (2-4, 8, 9, 20) and/or organ injury (five trials) (2-4, 19, 24) . However, these trials presented either differing measures of these outcomes or only p values without analyzable data (Supplemental Table 3 , Supplemental Digital Content 1, http://links.lww. com/CCM/A693). Thus, it was not possible to combine these data and formulate overall conclusions. However, only two of these eight trials noted significant beneficial effects: one on speed to shock reversal and on time to development of new organ failure (3) and another on the reduction in organ injury scores over time (19) .
Seven trials presented data regarding the effect of anti-TNF agents on blood TNF (four trials) (3, (18) (19) (20) and/or IL-6 cytokine levels (five trials) ( Table 3 ) (6, 8, 19, 20, 24) . Treatment was reported to significantly lower one or both of these cytokine levels compared with controls in six of the seven trials (TNF in four trials [3, [18] [19] [20] ; IL-6 in four trials [6, 19, 20, 24] ).
Serious Adverse Events, Secondary Infections, and Development of Antibodies
In the seven trials reporting data regarding the effects of anti-TNF agents on the prevalence of serious adverse events (SAEs), these did not differ Effects of the four different types of antitumor necrosis factor (anti-TNF) agents, including TNF monoclonal antibodies (TNF-mAb), TNF polyclonal antibodies (TNF-pAb), low-molecular-weight TNF soluble receptor (TNFsr-p55), and high-molecular-weight TNFsr (TNFsr-p75) in randomized controlled trials. The level of consistency among the trials (I 2 value) and relative risk (RR, diamond) of death and 95% CI among the trials for each type of agent are shown. The effects of each type of anti-TNF agent were consistent across the trials testing them. TNF-mAb, the most frequently studied (10 trials), was itself alone associated with a significant increase in the RR (95% CI) (p = 0.015). significantly across trials (I 2 = 0, p = 0.70) ( Fig. 3) (2, 4, 9, 18, 19, 24, 25) . Overall, the RR of having an SAE tended to be decreased with anti-TNF agents compared with controls (RR, 0.955 [0.914-0.999]; p = 0.046). In one trial reporting only the prevalence of adverse events, there was no significant difference comparing treatment and control groups (121 of 386 (31.3%) vs 48 of 167 (28.7%), respectively; p = 0.54) (3). Consistent with these findings, six additional trials not providing numerical data did report that there were no significant differences in adverse or serious events comparing treatment to controls. In eight trials reporting on secondary infections (2-4, 7, 9, 18, 19, 25) , only two trials provided analyzable data to compare the number of patients with secondary infection in treatment versus control groups. In both trials, the prevalence of secondary infection was not increased with treatment compared with control (18, 19) . In the remaining six trials, rates of infection were not reported increased with treatment.
Seven trials testing TNF-mAb reported that from 16% to 98% of patients developed human anti-mouse antibodies (median [IQR], 51% [32-88%]) (2, 3, 5, 6, 19, 23, 24) . In two trials testing TNF-pAb, 41% of treatment patients in one trial and 15% in another trial developed antiovine antibodies (18, 20) . Finally, in the one trial testing TNFsr-p75, 15% of patients developed antibodies to treatment (10) .
Potential Sources of bias
A funnel plot of the 15 trials (Supplemental Fig. 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/A693) and formal testing using Egger's regression methods (p = 0.50) did not suggest publication bias. Fourteen of the trials analyzed were funded by the manufacturer of the anti-TNF agent tested and for each at least one contributing author reported receiving financial support from the manufacturer (Supplemental Table 4 , Supplemental Digital Content 1, http://links.lww.com/ CCM/A693) (2-7, 9, 10, 18-20, 25) . Five trials presented the number of treated patients lost to follow-up (Supplemental Table 4 , Supplemental Digital Content 1, http://links.lww.com/ CCM/A693) (2, 4, 8, 18, 25) . When missing placebo and anti-TNF treatment patients were considered survivors or nonsurvivors, respectively, the effect of anti-TNF agents on the RR of death across all 15 trials remained significant (0.94 [0.89, 0.99], p = 0.02). The number of patients initially receiving appropriate antibiotics for a documented source of infection (2-4, 10, 24) and the number of patients having surgery (2, 3, 6, 10, 19, 20, 24) were only recorded in five and seven studies, respectively (data not shown). Across these studies, the RR of receiving either appropriate antibiotics or surgery in patients receiving anti-TNF agents did not differ significantly compared with control (0.99 [0.96-1.02], p = 0.63 and 1.01 [0.94-1.08], p = 0.83, respectively).
DISCUSSION
Across 15 clinical trials in sepsis, selective anti-TNF agents had effects on survival, which did not differ significantly and which overall decreased the RR (95% CI) of death significantly (0.93 [0.88-0.98], p = 0.01). In subgroup analysis, trials with greater enrollment (> 400 patients with sepsis, n = 7) demonstrated significant overall beneficial treatment effects. Anti-TNF agents also appeared to have minimal risk as the number of SAEs or infectious complications was not increased across trials reporting such data (n = 7 and 8, respectively). Six other trials, although not providing data, reported that adverse events were also not increased with treatment. These findings suggest that agents selectively inhibiting TNF have a favorable benefit-to-risk ratio in patients with sepsis, and large trials are necessary to capture this beneficial effect. Consistent with this, TNF-mAb, which was studied in more trials and patients than other anti-TNF agents analyzed (10 trials and 6,818 patients) and in several of the largest trials, by itself demonstrated a significant overall survival benefit. Based on these findings, failure of anti-TNF agents to show benefit in any of the 15 individual trials appears largely related to insufficient patient sample sizes. A power analysis shows that for a similar agent in a septic population with a mortality rate like the one studied (38%), 10,000 patients would be required to show a significant survival benefit at a 0.05 level (two sided) with an 80% power. If as suggested by a recent large survey conducted by the Surviving Sepsis Campaign (25,000 patients), the mortality rate in sepsis is now closer to 32%, then as many as 14,000 patients might be required for study (26) . Yet, the largest trial investigating these anti-TNF agents included only 2,634 patients (19) .
The finding that trials testing these types of anti-TNF agents may require 10,000 or more patients with sepsis to demonstrate significant efficacy raises several concerns. Enrolling such a large number of patients would be made easier by limiting trial exclusion criteria. Although anti-TNF agents did not have 
Figure 3.
Effects of antitumor necrosis factor (anti-TNF) therapies on the relative risk (RR, diamond) of death (95% CI) of increasing the number of serious adverse events in the seven trials reporting such data. The level of consistency among the trials (I 2 value) and RR of serious adverse events and 95% CI among the trials are shown. Serious adverse events were not increased with treatment and actually showed a small but significant reduction. mAb = monoclonal antibody, pAb = polyclonal antibody, p55 = low-molecular-weight TNF.
significantly harmful effects in any subgroup described, such analysis was limited. Whether anti-TNF therapy might prove harmful in an as yet unidentified subgroup if investigated in a larger number of less stringently enrolled patients with sepsis is unknown. Also, a study enrolling 10,000 or more patients with sepsis may require prolonged enrollment across many centers, which could confound results. Reassuringly, of the 15 trials analyzed, the one which enrolled patients over the longest period (3.5 yr) and across multiple centers (157) demonstrated benefit with treatment approaching significance (19) . It is also notable that the recent Surviving Sepsis Campaign survey reported enrolling more than 25,000 patients with sepsis over only 5 years (January 2005-January 2010) or a little over 5,000 patients per year (26) . If only half of these patients were eligible for a treatment study, then for a class of agents such as anti-TNF ones, with what appear to be limited adverse effects but wide applicability, it might have only required 4-5 years to enroll 10,000-12,500 patients in a treatment study. Ideally this would be a randomized controlled trial. Logistically such a study would be difficult and safety monitoring would be critical. Funding might also require aid from governmental agencies with an interest in public health as has been the case for other sepsis therapies like fluid and vasopressor support (27) . However, such a study appears feasible and could be done in a reasonable period of time.
Whether enrollment in future trials of selective anti-TNF agents could be limited by targeting treatment to more responsive subgroups is unclear from this analysis. For example, although evidence has suggested that both mediator selective and nonselective anti-inflammatory agents have greater efficacy in septic patients with a higher risk of death (28) (29) (30) , in this meta-analysis anti-TNF agents had similar effects across trials with a relatively wide range of risk (i.e., control mortality rates from 26% to 60%). However, even a control mortality rate of 26% represents a relatively high risk of death. Prior analysis has suggested that anti-inflammatory agents may only lose their beneficial effects or show harm when mortality rates are less than 20-22% (28, 30, 31) . Thus, if studies with a lower mortality rates had been available, it is possible a relationship between risk of death and treatment effects might have been noted. Although only two trials provided data regarding the effects of therapy based on a predicted risk of death score, anti-TNF therapy had significant benefit with a higher but not lower risk of death in one of these. Also, in the four trials stratifying patients based on the presence or absence of shock at enrollment, anti-TNF agents had an effect on the side of benefit in those with shock but not in those without shock, although this did not reach significance. Variability in the effect of therapy in subgroups based on blood TNF and IL-6 levels and type of bacterial infection precluded analysis regarding a patient subgroup which anti-TNF agents might be targeted against. Certainly, if a large prospective study of anti-TNF agents were to be undertaken, examining the effects of therapy based on prospective measures, such as risk prediction scores, the presence or absence of shock or organ injury, and cytokine or other biomarker levels, would be important.
Despite the size of a single trial necessary to confirm the potential benefit of anti-TNF agents in sepsis, such a trial appears warranted. The overall treatment effect noted with anti-TNF agents in this analysis in combination with the observed overall control mortality rate (38%) indicates that if 37 patients with sepsis were treated, one death would be prevented. Conservatively then, if 400,000 patients in whom severe sepsis or septic shock develop annually in the United States with a median mortality rate of 38%, approximately 4,000 of these patients would be saved with anti-TNF therapy. Even if the mortality rate from sepsis has decreased over time to the level suggested by the recent Surviving Sepsis Campaign survey (32%), then based on the NNT at this lower rate (i.e., 45), approximately 3,000 of the 400,000 patients described above would be saved with anti-TNF therapy. However, broad use of anti-TNF agents would depend in part on the therapy's cost.
The basis for the survival benefit noted with anti-TNF agents remains unclear. Consistent with their recognized antiinflammatory effects, there was evidence in this meta-analysis that treatment reduced blood TNF and IL-6 cytokine levels. In six of the seven trials reporting such data (Table 3) , anti-TNF therapies were noted to significantly reduce one or both of these cytokines. In three of the four studies showing reductions in TNF levels, anti-TNF therapies had effects on the side of benefit. Also, in the largest of the 15 trials (Panacek et al [19] )-the one showing benefit closest to significance-TNF and IL-6 levels were lower with treatment. However for other secondary endpoint data, although limited, it was not evident that anti-TNF agents resulted in either greater resolution of shock or organ injury. Notably, although administration of an anti-inflammatory agent in patients with sepsis might suppress host defenses and increase risk, the prevalence of SAEs was not increased with anti-TNF agents. Also, secondary infection was not reported significantly increased. However, the methods used to track infectious complications were not provided in most trials, and insufficient methodology may have confounded these findings. Use of selective anti-TNF agents in patients with arthritis treated over longer periods than in these sepsis trials has been associated with increased risk of infection (1) . Increased risk related to the primary or a secondary infection must still be a concern if anti-TNF agents are considered for sepsis.
When compared with septic controls, the three doses of TNFsr-p75 studied in the only trial testing this agent were reported to produce a significant dose-dependent increase in mortality (p = 0.02) (10) . However, as also noted in the original publication, when these three TNFsr-p75 doses were either compared with each other or combined and compared with control, significant differences were not noted. Nonetheless, the significant dose-dependent effect noted is concerning and, in comparison with the other types of anti-TNF agents investigated, raises the possibility that this particular one may be associated with increased risk. It is notable though, that when examining results of 15 trials, it is not unexpected that by chance one of the smaller trials (141 patients) could fall on the side of harm and even reach statistical significance. Regardless, TNFsr-p75 has a known infection risk when used for other www.ccmjournal.org
October 2013 • Volume 41 • Number 10 inflammatory conditions and should not be tested in patients with sepsis until the result of this single sepsis trial is better understood.
This study has limitations. There were limited data from published reports on relevant secondary endpoints to elucidate the nature of the survival benefit with anti-TNF therapy. Likewise, the methods to record SAEs, most importantly secondary infection, were missing or incomplete. Thus, any assessment of risk with treatment across trials cannot be made with assurance. Four trials reported losing patients to follow-up. However, even after accounting for these lost patients, anti-TNF agents still had an overall significant survival benefit. Fourteen of the trials analyzed received support from the manufacturer of the anti-TNF agent tested, and for each of these, one or more authors had financial relationships with the manufacturer. Despite this potential for bias, none of these trials individually reported a significant survival benefit. Finally, in a recent Phase 2b trial, treatment with a polyclonal antibody to TNF (AZD9773) was reported in the news media to not show significant improvement in survival compared with placebo (32) . Although this trial was designed to only enroll 300 patients, efforts to obtain additional information regarding enrollment and results were unsuccessful (33) .
In conclusion, selective anti-TNF agents as a class produced a significant overall survival benefit in patients with sepsis, and these agents have continued to undergo investigation in sepsis. Based on this meta-analysis, however, unless such trials are large enough, it is unlikely that they will demonstrate significant survival benefits. Ultimately, though the potential for benefit with selective anti-TNF agents suggests that conducting sufficiently large sepsis trials testing them, while logistically complex, might be warranted.
